Drugs / ibipinabant
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00388609 | Nov 2006 → Sep 2007 | obesity disorder | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00541567 | Mar 2008 → Jun 2010 | type 2 diabetes mellitus | Solvay Pharmaceuticals | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ibipinabant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00541567 ↗ |
| Known as | BMS-646256 | “BMS-646256 in Obese and Overweight Type 2 Diabetics” NCT00541567 ↗ |
| Known as | SLV-319 | ChEMBL registry synonym — accepted as the source's own label CHEMBL412262 ↗ |
| Action | Inhibit | “Cannabinoid CB1 receptor antagonist” CHEMBL412262 ↗ |
| Modality | Small molecule | — CHEMBL412262 ↗ |
| Route | Oral | “oral, tablet, once daily” NCT00541567 ↗ |
| Target | CNR1 | “Cannabinoid CB1 receptor antagonist” CHEMBL412262 ↗ |